{"entity":{"type":"insider","cik":"0001628970","url":"/insider/0001628970","json_url":"/insider/0001628970.json","name":"ASADORIAN RAFFI","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":9,"first":"2017-09-11","last":"2026-02-20","span_basis":"filed_date"},"name_variants":[{"name":"ASADORIAN RAFFI","source":"filing","n_filings":9,"first_seen":"2017-09-11","last_seen":"2026-02-20"}],"transactions":[{"id":5787833,"accession":"0001628970-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628970-26-000002","line_url":"/filing/0001628970-26-000002#line-2","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"TALPHERA, INC.","issuer_ticker":"TLPH","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Commom Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45000.0,"shares_display":"45,000","price_per_share":0.8123,"price_display":"0.81","price_state":"stated","total_value":36553.5,"total_display":"36,553.50","total_whole":"36,554","shares_owned_after":91256.0,"shares_owned_after_display":"91,256","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-12","filed_date":"2026-02-20","scope":"insider"},{"id":2257579,"accession":"0001415889-24-027990","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-027990","line_url":"/filing/0001415889-24-027990#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"TALPHERA, INC.","issuer_ticker":"TLPH","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":155.0,"shares_display":"155","price_per_share":0.767,"price_display":"0.77","price_state":"stated","total_value":118.885,"total_display":"118.88","total_whole":"119","shares_owned_after":37578.0,"shares_owned_after_display":"37,578","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-02","filed_date":"2024-12-02","scope":"insider"},{"id":8023747,"accession":"0001209191-19-015634","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-015634","line_url":"/filing/0001209191-19-015634#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3647.0,"shares_display":"3,647","price_per_share":2.81,"price_display":"2.81","price_state":"stated","total_value":10248.07,"total_display":"10,248.07","total_whole":"10,248","shares_owned_after":124397.0,"shares_owned_after_display":"124,397","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-28","filed_date":"2019-03-04","scope":"insider"},{"id":6480047,"accession":"0001209191-18-062870","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-062870","line_url":"/filing/0001209191-18-062870#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.7766,"price_display":"2.78","price_state":"stated","total_value":13883.0,"total_display":"13,883.00","total_whole":"13,883","shares_owned_after":52000.0,"shares_owned_after_display":"52,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-14","filed_date":"2018-12-17","scope":"insider"},{"id":6869627,"accession":"0001209191-18-058155","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-058155","line_url":"/filing/0001209191-18-058155#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.1292,"price_display":"3.13","price_state":"stated","total_value":15646.0,"total_display":"15,646.00","total_whole":"15,646","shares_owned_after":47000.0,"shares_owned_after_display":"47,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-13","filed_date":"2018-11-13","scope":"insider"},{"id":6661605,"accession":"0001209191-18-045578","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-045578","line_url":"/filing/0001209191-18-045578#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.745,"price_display":"2.74","price_state":"stated","total_value":13725.0,"total_display":"13,725.00","total_whole":"13,725","shares_owned_after":32000.0,"shares_owned_after_display":"32,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-06","filed_date":"2018-08-06","scope":"insider"},{"id":6250737,"accession":"0000899243-18-014190","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-014190","line_url":"/filing/0000899243-18-014190#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.1845,"price_display":"3.18","price_state":"stated","total_value":15922.5,"total_display":"15,922.50","total_whole":"15,923","shares_owned_after":27000.0,"shares_owned_after_display":"27,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-25","filed_date":"2018-05-29","scope":"insider"},{"id":4217573,"accession":"0000899243-17-026161","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-026161","line_url":"/filing/0000899243-17-026161#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.9421,"price_display":"1.94","price_state":"stated","total_value":9710.5,"total_display":"9,710.50","total_whole":"9,711","shares_owned_after":12000.0,"shares_owned_after_display":"12,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-13","filed_date":"2017-11-14","scope":"insider"},{"id":4291943,"accession":"0001437749-17-015834","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-17-015834","line_url":"/filing/0001437749-17-015834#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001628970","owner_name":"ASADORIAN RAFFI","owner_display_name":"ASADORIAN RAFFI","owner_url":"/insider/0001628970","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7000.0,"shares_display":"7,000","price_per_share":3.2436,"price_display":"3.24","price_state":"stated","total_value":22705.2,"total_display":"22,705.20","total_whole":"22,705","shares_owned_after":7000.0,"shares_owned_after_display":"7,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-11","filed_date":"2017-09-11","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":9,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":9},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"TALPHERA, INC.","url":"/issuer/0001427925","role":"Officer (Chief Financial Officer)","n_filings":9,"first_seen":"2017-09-11","last_seen":"2026-02-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001628970","retrieved_at":"2026-08-25T19:26:10+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}